In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae

Clicks: 261
ID: 5798
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1,118 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae Marlene Hipp, Irene BurckhardtDepartment for Infectious Diseases, Microbiology and Hygiene, University Hospital of Heidelberg, Heidelberg, GermanyBackground: Since the first isolation of Streptococcus pneumoniae with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.Methods: Since 2009 clinical pneumococcal strains have been collected at the Center for Infectious Diseases, Heidelberg University Hospital, Germany. In this study, 56 of these strains were chosen due to their decreased penicillin susceptibility (minimal inhibitory concentration (MIC)≥0.12 μg/mL). Sixteen of these strains even showed an MIC of ≥2 μg/mL. We examined the in vitro activity of newer antimicrobials known to be active against Gram-positive bacteria. For this purpose MICs of ceftaroline, ceftobiprole, dalbavancin, delafloxacin, eravacycline, tedizolid, and telavancin were determined and evaluated.Results: All of the 7 antimicrobial agents inhibited pneumococcal growth at concentrations of 0.5 μg/mL or lower. Currently, clinical breakpoints are only available for two substances, ceftaroline and ceftobiprole. According to these breakpoints, all MICs were below the susceptibility breakpoint; however, there was a correlation between high penicillin MICs (≥2 μg/mL) and MICs near the ceftaroline and ceftobiprole susceptibility breakpoint. The other agents showed very promising effects against all tested strains with the lowest MIC90 of 0.002 μg/mL for telavancin.Conclusion: Consequently, this study demonstrates the promising in vitro activity of newer antimicrobials against penicillin non-susceptible strains of S. pneumoniae.Keywords: Streptococcus pneumoniae, penicillin resistance, susceptibility testing
Reference Key
marlene2019ininfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marlene Hipp;Irene Burckhardt and
Journal Infection and drug resistance
Year 2019
DOI
10.2147/IDR.S202789
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.